Seelos Therapeutics, Inc.
SEELDelisted Apr 4, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001017491
Seelos Therapeutics, Inc. was delisted on Apr 4, 2025; its insiders filed their last Form 4 on Mar 1, 2024; 23 institutions reported holding it in 13F filings for Q2 2024, worth $129.4K in total; no superinvestor held it.
13F holders, Q4 2024
Institutional positions in Seelos Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
SEEL is no longer listed, and 13F filings after Q2 2024 list far fewer holders. See Q2 2024
- Institutional holders
- 3
- −11 vs. Q3 2024
- Shares held
- 20.6K
- −18.0K (−46.6%) vs. Q3 2024
- Total value
- $4.77K
- −$140.2K (−96.7%) vs. Q3 2024
- New holders
- 1
- 1 more added
- Sold out
- 12
- 0 more reduced
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SEEL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 1 | $0 |
| Q4 2025 | 1 | $0 |
| Q3 2025 | 1 | $0 |
| Q2 2025 | 1 | $0 |
| Q1 2025 | 1 | $0 |
| Q4 2024 | 3 | $4.77K |
| Q3 2024 | 15 | $145.2K |
| Q2 2024 | 23 | $129.4K |
| Q1 2024 | 36 | $1.55M |
| Q4 2023 | 39 | $2.48M |
| Q3 2023 | 82 | $7.01M |
| Q2 2023 | 83 | $27.1M |
| Q1 2023 | 80 | $15.1M |
| Q4 2022 | 80 | $15.6M |
| Q3 2022 | 85 | $28.0M |
| Q2 2022 | 86 | $21.3M |
| Q1 2022 | 92 | $33.0M |
| Q4 2021 | 97 | $65.9M |
| Q3 2021 | 110 | $98.2M |
| Q2 2021 | 105 | $107.8M |
| Q1 2021 | 73 | $124.8M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Seelos Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AdvisorShares Investments LLC | 20,543 | $4.77K | 0.00% | +2,430+13.4% | Added |
| Vermillion & White Wealth Management Group, LLC | 7 | $2 | 0.00% | 00.0% | Unchanged |
| Flagship Wealth Advisors, LLC | 73 | $0 | 0.00% | +73 | New |
| Modera Wealth Management, LLC | 0 | $0 | 0.00% | −10,805−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −8,477−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −675−100.0% | Sold out |
| BlackRock, Inc. | 0 | $0 | 0.00% | −354−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −95−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −32−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −31−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| Crewe Advisors LLC | 0 | $0 | 0.00% | −7−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Newbridge Financial Services Group, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Carmichael Hill & Associates, Inc. | – | – | – | – | Not filed |